Bullish Analyst Opinion on Dyne (DYNE) Follows Rare Disease Drug Progress in Japan

Dyne Therapeutics Inc. (NASDAQ:DYN) is one of the 13 hot stocks to buy with the highest upside potential. As of February 13, nearly 90% of analysts who cover the stock have assigned a Buy or equivalent rating. The consensus 1-year median price target of $39.5 implies a 138% upside. Earlier, on January 21, Francois Brisebois from LifeSci Capital reiterated a Buy rating on Dyne Therapeutics Inc. (NASDAQ:DYN), with a price target of $44. Meanwhile, on January 20, Dyne Therapeutics Inc. (NASDAQ:DYN) announce ...